miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma

Lou, Ning; Ruan, Anming; Qiu, Bin; Bao, Lin; Xu, Yan; Zhao, Yan; Sun, Rulin; Zhang, Santao; Xu, G.; Ruan, Hailong; Yuan, Chunrong; Wang, Han; Shi, Hangchuan; Yang, Hongmei; Zhang, Xiaoping

doi:10.1016/j.urolonc.2016.07.012

Cited by 50 publications

(48 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, the expression of SDC3 was directly regulated by miR-144-5p, and its upregulation enhanced RCC cell invasiveness. Lou N et al reported a significantly higher level of miR-144-3p in 106 ccRCC plasmas as compared with healthy individuals, suggesting the role of miR-144-3p as a novel and unique plasma biomarker for the diagnosis of ccRCC [129]. Overall, studies showed that miR-144 could function as both tumor suppressor and oncogene, depending on the target gene and pathways involved.…”

Section: Mir-144 In Renal Cell Carcinomamentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small and non-coding RNAs that display aberrant expression in the tissue and plasma of cancer patients when tested in comparison to healthy individuals. In past decades, research data proposed that miRNAs could be diagnostic and prognostic biomarkers in cancer patients. It has been confirmed that miRNAs can act either as oncogenes by silencing tumor inhibitors or as tumor suppressors by targeting oncoproteins. MiR-144s are located in the chromosomal region 17q11.2, which is subject to significant damage in many types of cancers. In this review, we assess the involvement of miR-144s in several cancer types by illustrating the possible target genes that are related to each cancer, and we also briefly describe the clinical applications of miR-144s as a diagnostic and prognostic tool in cancers.Int. J. Mol. Sci. 2020, 21, 2578 2 of 23 of a mRNA molecule [3]. MiRNAs indicate a new perspective in the study of cancers. More than 50% of miRNA genes were discovered to be located within the genomic regions that are involved in cancers, suggesting their role in human cancer pathogenesis. In pathological conditions, MiRNAs can negatively regulate gene expression and they are associated with tumor growth, apoptosis, invasion, and metastasis. In the past, several studies have indicated the ability of miRNAs in the inhibition of tumors as a critical option for the improvement of cancer therapy [4,5]. Tumor activator miRNAs, called oncomiRs, are overexpressed in various cancers. On the contrary, suppressive tumor miRNAs are underexpressed [6][7][8]. Among several miRNAs assessed, miR-144s seem to have a role in several cancers. These miRNAs are located in the chromosomal region 17q11.2, being significantly destroyed in many types of cancers. The predicted stem-loop structure of miR-144s recognized by the miRBase (http://mirbase.org/) is shown in Figure 1A. The miR-144 hairpin gives rise to the "guide strand" miR-144-5p and the sister "passenger" strand miR-144-3p ( Figure 1B).

show abstract

Section: Mir-144 In Renal Cell Carcinomamentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…It has been shown that circulating miRNAs may act as biomarkers of gait speed in obese adults [19] or have a prognostic role in cancer [20]. More recently, several articles confirmed that plasma miRNAs could be biomarkers of RCC, such as miR-144À3p and miR-210 [21,22]. Previous studies have demonstrated 2.6.…”

Section: Introductionmentioning

confidence: 99%

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

et al. 2020

View full text Add to dashboard Cite

A B S T R A C TBackground: Lipid accumulation has been highlighted in cancer development and progression, but the exact mechanism remains unclear in renal cell carcinoma (RCC). MicroRNAs (miRNAs) have been confirmed to participate in the pathological processes of cancers, including tumour occurrence and inhibition. However, the role and mechanism of miR-765 have not been elucidated in clear cell renal cell carcinoma (ccRCC). Methods: Using The Cancer Genome Atlas (TCGA) database and qRT-PCR, we investigated differences in miR-765 and proteolipid protein 2 (PLP2) expression, as well as their clinical relevance. To investigate the function of miR-765 and PLP2 in ccRCC, we performed in vitro and in vivo experiments to explore their biological functions in ccRCC. Findings: In this study, we showed that miR-765 was upregulated in the plasma of ccRCC patients after tumour resection. Consistently, ccRCC tissues had low expression of miR-765 when compared with corresponding non-cancerous tissues. Overexpression of miR-765 suppressed cell proliferation and metastasis in vitro and in vivo. Mechanistic studies demonstrated that PLP2 was a direct target gene of miR-765. PLP2 was highly expressed in ccRCC tissues, and high PLP2 levels were positively correlated with higher tumour stage and grade and poor prognosis. PLP2 expression was negatively correlated with the miR-765 level in patient samples. We further showed that PLP2 restrained the cell metastasis and proliferation induced by miR-765 and reduced the lipid-eliminating effects of miR-765 in renal cancer cells. Interpretation: Our findings suggest that miR-765 may function as a tumour suppressor and eliminate lipids in clear cell renal cell carcinoma by targeting PLP2. EBioMedicine journal homepage: www.elsevier.com/locate/ebiom that miR-765 inhibits osteosarcoma [23] and tongue squamous cell carcinoma [24]. Nevertheless, to the best of our knowledge, there is still no relevant research about the role of miR-765 in ccRCC. We found that the plasma level of miR-765 was upregulated after tumour resection in ccRCC patients and that ccRCC tissues had a low level of miR-765 compared with corresponding non-ccerous tissues. The present study systematically describes the function and role of miR-765 in ccRCC. Functionally, miR-765 inhibited RCC cell proliferation, migration and invasion in vitro and in vivo. Mechanistically, miR-765 serves as a tumour suppressor and eliminates lipids by downregulating PLP2 in ccRCC. Our findings reveal that the miR-765-PLP2 axis may be a biomarker and a therapeutic target for ccRCC. Materials and methods Patient samples and cellsThirty-six clear cell renal cell carcinoma (ccRCC) patient surgical specimens, 18 non-ccRCC (nccRCC) patient surgical specimens and 18 blood plasma samples (preoperative and operational day 7 without chemotherapy or radiotherapy for ccRCC) were obtained from

show abstract

“…However, other studies indicate that miR-144-3p increased in nasopharyngeal carcinoma as an oncomiRNA [38]. We previously found that miR-144-3p was the only one upregulated miRNA both in clear cell renal cell carcinoma (ccRCC) tissue samples matched with normal kidney tissues and in paired preoperative matched with postoperative plasmas [32, 33]. However, the mean level of miR-144-3p was downregulated in non-clear-renal-cell-carcinoma tissues compared with adjacent normal tissues, but had no statistical significance.…”

Section: Discussionmentioning

confidence: 99%

“…The plasma miR-144-3p levels significantly decreased after surgery in ccRCC patients [32]. Furthermore, the miR-144-3p levels in ccRCC tumor tissues obviously increased when compared with adjacent normal tissues in tissues microarray analysis and ccRCC tissues [33].…”

Section: Introductionmentioning

confidence: 99%

Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A

Xiao

Lou

Ruan

et al. 2017

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: We previously performed microRNA (miRNA) microarray to identify effective indicators of clear cell renal cell carcinoma (ccRCC) tissue samples and preoperative/postoperative plasma in which we identified miR-144-3p as an oncomiRNA. However, the molecular mechanism of miR-144-3p remains unclear. This study aims to explore the roles of miR-144-3p in the invasion, migration and Sunitinib-resistance in ccRCC and to elucidate the underlying mechanisms. Methods: Gain and loss of function approaches were used to investigate the cell proliferation, cycle distribution, clonogenicity, migration, invasion, chemosensitivity of miR-144-3p in vitro. The xenograft model was used to assess the effects of miR-144-3p overexpression on tumorigenesis. Bioinformatics analysis and dual-luciferase reporter assay were used to indentify AT-rich interactive domain 1A (ARID1A) as a direct target gene of miR-144-3p. Quantitative RT-PCR, Western blotting, and immunohistochemical (IHC) staining were used to explore ARID1A expression level of the mRNA and protein. Results: We found that miR-144-3p overexpression enhanced cell proliferation, clonogenicity, migration, invasion, and chemoresistance in ccRCC cells. Notably, the oncotumor activities of miR-144-3p were mediated by repressing the expression of ARID1A. The downregulation of ARIDIA could promote the function of miR-144-3p in cell proliferation, metastasis and chemoresistance. Consistently, ARID1A mRNA and protein levels were decreased in ccRCC and in nude mice, and they negatively correlated with miR-144-3p. Conclusion: Higher miR-144-3p may enhance malignancy and resistance to Sunitinib in ccRCC by targeting ARID1A, the observations may uncover novel strategies of ccRCC treatment.

show abstract

miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma

Cited by 50 publications

References 30 publications

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A

Contact Info

Product

Resources

About